Defining secondary progressive multiple sclerosis

Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, Tim Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Marc Girard, Pierre Duquette, Alexandre Prat, Alessandra Lugaresi, François Grand'Maison, Pierre Grammond, Raymond Hupperts, Raed Alroughani, Patrizia Sola, Cavit Boz, Eugenio Pucci, Jeanette Lechner-ScottRoberto Bergamaschi, Celia Oreja-Guevara, Gerardo Iuliano, Vincent Van Pesch, Franco Granella, Cristina Ramo-Tello, Daniele Spitaleri, Thor Petersen, Mark Slee, Freek Verheul, Radek Ampapa, Maria Pia Amato, Pamela McCombe, Steve Vucic, José Luis Sánchez-Menoyo, Edgardo Cristiano, Michael H. Barnett, Suzanne Hodgkinson, Javier Olascoaga, Maria Laura Saladino, Orla Gray, Cameron Shaw, Fraser Moore, Helmut Butzkueven, Tomas Kalincik, MSBase Study Group

Research output: Contribution to journalArticle

Abstract

A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis: sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87% compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70% reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95% confidence interval 32-33.6) after disease onset compared with the physicians' diagnosis at 36 (35-39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.

Original languageEnglish
Pages (from-to)2395-405
Number of pages11
JournalBrain
Volume139
Issue numberPt 9
DOIs
Publication statusPublished - Sep 2016

Fingerprint

Chronic Progressive Multiple Sclerosis
Recurrence
Observational Studies
Cohort Studies
Clinical Trials
Confidence Intervals
Physicians

Keywords

  • Journal Article

Cite this

Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., ... MSBase Study Group (2016). Defining secondary progressive multiple sclerosis. Brain, 139(Pt 9), 2395-405. https://doi.org/10.1093/brain/aww173

Defining secondary progressive multiple sclerosis. / Lorscheider, Johannes; Buzzard, Katherine; Jokubaitis, Vilija; Spelman, Tim; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Izquierdo, Guillermo; Girard, Marc; Duquette, Pierre; Prat, Alexandre; Lugaresi, Alessandra; Grand'Maison, François; Grammond, Pierre; Hupperts, Raymond; Alroughani, Raed; Sola, Patrizia; Boz, Cavit; Pucci, Eugenio; Lechner-Scott, Jeanette; Bergamaschi, Roberto; Oreja-Guevara, Celia; Iuliano, Gerardo; Pesch, Vincent Van; Granella, Franco; Ramo-Tello, Cristina; Spitaleri, Daniele; Petersen, Thor; Slee, Mark; Verheul, Freek; Ampapa, Radek; Amato, Maria Pia; McCombe, Pamela; Vucic, Steve; Sánchez-Menoyo, José Luis; Cristiano, Edgardo; Barnett, Michael H.; Hodgkinson, Suzanne; Olascoaga, Javier; Saladino, Maria Laura; Gray, Orla; Shaw, Cameron; Moore, Fraser; Butzkueven, Helmut; Kalincik, Tomas; MSBase Study Group.

In: Brain, Vol. 139, No. Pt 9, 09.2016, p. 2395-405.

Research output: Contribution to journalArticle

Lorscheider, J, Buzzard, K, Jokubaitis, V, Spelman, T, Havrdova, E, Horakova, D, Trojano, M, Izquierdo, G, Girard, M, Duquette, P, Prat, A, Lugaresi, A, Grand'Maison, F, Grammond, P, Hupperts, R, Alroughani, R, Sola, P, Boz, C, Pucci, E, Lechner-Scott, J, Bergamaschi, R, Oreja-Guevara, C, Iuliano, G, Pesch, VV, Granella, F, Ramo-Tello, C, Spitaleri, D, Petersen, T, Slee, M, Verheul, F, Ampapa, R, Amato, MP, McCombe, P, Vucic, S, Sánchez-Menoyo, JL, Cristiano, E, Barnett, MH, Hodgkinson, S, Olascoaga, J, Saladino, ML, Gray, O, Shaw, C, Moore, F, Butzkueven, H, Kalincik, T & MSBase Study Group 2016, 'Defining secondary progressive multiple sclerosis', Brain, vol. 139, no. Pt 9, pp. 2395-405. https://doi.org/10.1093/brain/aww173
Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D et al. Defining secondary progressive multiple sclerosis. Brain. 2016 Sep;139(Pt 9):2395-405. https://doi.org/10.1093/brain/aww173
Lorscheider, Johannes ; Buzzard, Katherine ; Jokubaitis, Vilija ; Spelman, Tim ; Havrdova, Eva ; Horakova, Dana ; Trojano, Maria ; Izquierdo, Guillermo ; Girard, Marc ; Duquette, Pierre ; Prat, Alexandre ; Lugaresi, Alessandra ; Grand'Maison, François ; Grammond, Pierre ; Hupperts, Raymond ; Alroughani, Raed ; Sola, Patrizia ; Boz, Cavit ; Pucci, Eugenio ; Lechner-Scott, Jeanette ; Bergamaschi, Roberto ; Oreja-Guevara, Celia ; Iuliano, Gerardo ; Pesch, Vincent Van ; Granella, Franco ; Ramo-Tello, Cristina ; Spitaleri, Daniele ; Petersen, Thor ; Slee, Mark ; Verheul, Freek ; Ampapa, Radek ; Amato, Maria Pia ; McCombe, Pamela ; Vucic, Steve ; Sánchez-Menoyo, José Luis ; Cristiano, Edgardo ; Barnett, Michael H. ; Hodgkinson, Suzanne ; Olascoaga, Javier ; Saladino, Maria Laura ; Gray, Orla ; Shaw, Cameron ; Moore, Fraser ; Butzkueven, Helmut ; Kalincik, Tomas ; MSBase Study Group. / Defining secondary progressive multiple sclerosis. In: Brain. 2016 ; Vol. 139, No. Pt 9. pp. 2395-405.
@article{22d64035d0f44ddebcd6d741abd9a172,
title = "Defining secondary progressive multiple sclerosis",
abstract = "A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis: sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87{\%} compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70{\%} reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95{\%} confidence interval 32-33.6) after disease onset compared with the physicians' diagnosis at 36 (35-39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.",
keywords = "Journal Article",
author = "Johannes Lorscheider and Katherine Buzzard and Vilija Jokubaitis and Tim Spelman and Eva Havrdova and Dana Horakova and Maria Trojano and Guillermo Izquierdo and Marc Girard and Pierre Duquette and Alexandre Prat and Alessandra Lugaresi and Fran{\cc}ois Grand'Maison and Pierre Grammond and Raymond Hupperts and Raed Alroughani and Patrizia Sola and Cavit Boz and Eugenio Pucci and Jeanette Lechner-Scott and Roberto Bergamaschi and Celia Oreja-Guevara and Gerardo Iuliano and Pesch, {Vincent Van} and Franco Granella and Cristina Ramo-Tello and Daniele Spitaleri and Thor Petersen and Mark Slee and Freek Verheul and Radek Ampapa and Amato, {Maria Pia} and Pamela McCombe and Steve Vucic and S{\'a}nchez-Menoyo, {Jos{\'e} Luis} and Edgardo Cristiano and Barnett, {Michael H.} and Suzanne Hodgkinson and Javier Olascoaga and Saladino, {Maria Laura} and Orla Gray and Cameron Shaw and Fraser Moore and Helmut Butzkueven and Tomas Kalincik and {MSBase Study Group}",
note = "Ricercatore distaccato presso IRCCS a seguito Convenzione esclusiva con Universit{\`a} di Bologna (Lugaresi Alessandra)",
year = "2016",
month = "9",
doi = "10.1093/brain/aww173",
language = "English",
volume = "139",
pages = "2395--405",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "Pt 9",

}

TY - JOUR

T1 - Defining secondary progressive multiple sclerosis

AU - Lorscheider, Johannes

AU - Buzzard, Katherine

AU - Jokubaitis, Vilija

AU - Spelman, Tim

AU - Havrdova, Eva

AU - Horakova, Dana

AU - Trojano, Maria

AU - Izquierdo, Guillermo

AU - Girard, Marc

AU - Duquette, Pierre

AU - Prat, Alexandre

AU - Lugaresi, Alessandra

AU - Grand'Maison, François

AU - Grammond, Pierre

AU - Hupperts, Raymond

AU - Alroughani, Raed

AU - Sola, Patrizia

AU - Boz, Cavit

AU - Pucci, Eugenio

AU - Lechner-Scott, Jeanette

AU - Bergamaschi, Roberto

AU - Oreja-Guevara, Celia

AU - Iuliano, Gerardo

AU - Pesch, Vincent Van

AU - Granella, Franco

AU - Ramo-Tello, Cristina

AU - Spitaleri, Daniele

AU - Petersen, Thor

AU - Slee, Mark

AU - Verheul, Freek

AU - Ampapa, Radek

AU - Amato, Maria Pia

AU - McCombe, Pamela

AU - Vucic, Steve

AU - Sánchez-Menoyo, José Luis

AU - Cristiano, Edgardo

AU - Barnett, Michael H.

AU - Hodgkinson, Suzanne

AU - Olascoaga, Javier

AU - Saladino, Maria Laura

AU - Gray, Orla

AU - Shaw, Cameron

AU - Moore, Fraser

AU - Butzkueven, Helmut

AU - Kalincik, Tomas

AU - MSBase Study Group

N1 - Ricercatore distaccato presso IRCCS a seguito Convenzione esclusiva con Università di Bologna (Lugaresi Alessandra)

PY - 2016/9

Y1 - 2016/9

N2 - A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis: sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87% compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70% reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95% confidence interval 32-33.6) after disease onset compared with the physicians' diagnosis at 36 (35-39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.

AB - A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis: sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87% compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70% reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95% confidence interval 32-33.6) after disease onset compared with the physicians' diagnosis at 36 (35-39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.

KW - Journal Article

U2 - 10.1093/brain/aww173

DO - 10.1093/brain/aww173

M3 - Article

C2 - 27401521

VL - 139

SP - 2395

EP - 2405

JO - Brain

JF - Brain

SN - 0006-8950

IS - Pt 9

ER -